Floatz logo

Tagraxofusp

Hematopoietic And Lymphoid System Neoplasm

Jacqueline Garcia, MDprotein_peptidePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

133 Active assets in the Hematopoietic And Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
OHSU Knight Cancer Institute
Phase 4BBB
Dexasone
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)
Gamida Cell ltd
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Tagraxofusp is also rated in:

CD4+/CD56+ hematodermic neoplasmActive
BB
Indicative · Phase 2
70 / 100
View asset →
acute myeloid leukemiaActive
B
Indicative · Phase 2
56 / 100
View asset →
acute undifferentiated leukemiaActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →